SEC Form 4 · accession 0001209191-19-010841
TEVA PHARMACEUTICAL INDUSTRIES LTD · TEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Matthew Stark
Officer — Exec. VP Chief Legal Officer
Period of report
Feb 14, 2019
Accepted (ET)
Feb 19, 2019 · 7:26 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000818686
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Feb 14, 2019 | M | 3,926 | — | A | 6,900 | D | |
| Ordinary SharesF1 | Feb 14, 2019 | S | 3,926 | $17.74 | D | 2,974 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF2,F4,F1 | — | Feb 14, 2019 | M | 3,926 | D | — | — | Ordinary Shares | 3,926 | 7,852 | D |
Explanation of responses
- F1The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- F2Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- F3The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F4Restricted share units were granted on February 14, 2017, with 3,926 vesting on each of February 14, 2019, February 14, 2020 and February 14, 2021.